trial · primary record
Azacitidine
Acute Myeloid Leukemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 153 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Measurable residual disease (MRD) undetectable complete remission (CR) |
| Registry ID | NCT05554393 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:02.841Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05554393
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- AZACITIDINE · approval
- Azacitidine · compound